Implication of deacetylases in histone deacetylation and development of their inhibitors

Place of work — Cell Biology, Sloan-
Kettering Institute,
Memorial Sloan-Kettering
Cancer Center, USA
Contacts — 1275 York Avenue, New York,
New York 10065, USA
(212) 639–6568
marksp@mskcc.org
http://www.mskcc.org/mskcc/
html/10595.cfm
Publications — Suberylanilide hydroxamic acid, an inhibitor of histone
deacetylase, suppresses the growth of
prostate cancer cells in vitro and in vivo. Butler L.M.,
Agus D.B., Scher H.I., Higgins B., Rose A., Cordon-Cardo C., Thaler H.T., Rifkind R.A., Marks P.A., Richon
v. M. Cancer Res. 2000 Sep
15;60(18):5165–70.
Histone deacetylase inhibitors. Marks P.A., Richon v. M.,
Miller T., Kelly W. K. Adv. Cancer
Res. 2004;137–168.
Intrinsic apoptotic and thioredoxin pathways in human
prostate cancer cell response to histone deacetylase inhibitor.
Xu, W., Ngo, L., Perez, G., Dokmanovic, M., Marks, P.A.
Proc. Natl. Acad Sci USA 103:
15540–15545, 2006.